PT-141 (Bremelanotide) – Comprehensive Research Overview (2026)
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analog of α-MSH and a melanocortin receptor agonist. It is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors (e.g., sildenafil), PT-141 acts centrally via melanocortin receptors in the brain to enhance sexual desire and arousal in both men and women, making it a unique tool in sexual health research.
→ View PT-141 (for laboratory research use only)
Mechanism of Action
- Activates melanocortin receptors (MC3R and MC4R) in the hypothalamus and limbic system.
- Increases dopaminergic signaling in reward and arousal circuits.
- Enhances sexual desire and motivation centrally, independent of vascular effects.
- Does not require sexual stimulation to initiate effects (unlike PDE5 inhibitors).
Clinical Evidence and Research Findings
FDA-approved (Vyleesi) for HSDD in premenopausal women based on Phase 3 trials showing significant improvements in sexual desire and reductions in distress. Off-label research in men shows improvements in erectile function and sexual desire, particularly in cases where PDE5 inhibitors are insufficient. It has a rapid onset (45–60 minutes) and duration of 6–12 hours.
→ Interested in researching PT-141? View Product Options
Benefits (Research & Clinical Observations)
- Enhanced sexual desire and arousal (men and women)
- Central mechanism independent of vascular effects
- Rapid onset (~45–60 minutes)
- Potential for erectile dysfunction research (especially PDE5 non-responders)
- FDA-approved for HSDD in women
Typical Dosing Protocols
- FDA-approved (women): 1.75 mg subcutaneous 45 minutes before sexual activity (max 1 dose/24h, 1 dose/month)
- Off-label (men): 0.5–2 mg subcutaneous 1–2 hours before activity
Safety Profile and Side Effects
Common side effects: Nausea (most common), flushing, headache, transient blood pressure changes. Nausea typically resolves within 2 hours. Contraindicated with cardiovascular disease or high-risk hypertension.
PT-141 vs Sildenafil vs Kisspeptin – Quick Comparison
| Aspect | PT-141 | Sildenafil | Kisspeptin |
|---|---|---|---|
| Mechanism | Central melanocortin agonist | PDE5 inhibitor (vascular) | HPG axis / GnRH stimulation |
| Primary Effect | Sexual desire & arousal | Erectile function | Hormonal / reproductive |
| FDA Status | Approved (HSDD, women) | Approved (ED) | Not approved |
Summary
PT-141 (Bremelanotide) is the only FDA-approved centrally-acting sexual desire enhancer, offering a unique mechanism complementary to vascular-based therapies. Its broad applicability in both men and women makes it a valuable research tool in sexual health. As with all compounds in this library, off-label use should only be considered under qualified medical supervision.
For Laboratory Research Use View PT-141 →
Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.